Stereotactic Radiosurgery for Spetzler-Martin Grade I and II Arteriovenous Malformations: International Society of Stereotactic Radiosurgery (ISRS) Practice Guideline.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 22 04 2019
accepted: 30 11 2019
pubmed: 18 2 2020
medline: 29 12 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

No guidelines have been published regarding stereotactic radiosurgery (SRS) in the management of Spetzler-Martin grade I and II arteriovenous malformations (AVMs). To establish SRS practice guidelines for grade I-II AVMs on the basis of a systematic literature review. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant search of Medline, Embase, and Scopus, 1986-2018, for publications reporting post-SRS outcomes in ≥10 grade I-II AVMs with a follow-up of ≥24 mo. Primary endpoints were obliteration and hemorrhage; secondary outcomes included Spetzler-Martin parameters, dosimetric variables, and "excellent" outcomes (defined as total obliteration without new post-SRS deficit). Of 447 abstracts screened, 8 were included (n = 1, level 2 evidence; n = 7, level 4 evidence), representing 1102 AVMs, of which 836 (76%) were grade II. Obliteration was achieved in 884 (80%) at a median of 37 mo; 66 hemorrhages (6%) occurred during a median follow-up of 68 mo. Total obliteration without hemorrhage was achieved in 78%. Of 836 grade II AVMs, Spetzler-Martin parameters were reported in 680: 377 were eloquent brain and 178 had deep venous drainage, totaling 555/680 (82%) high-risk SRS-treated grade II AVMs. The literature regarding SRS for grade I-II AVM is low quality, limiting interpretation. Cautiously, we observed that SRS appears to be a safe, effective treatment for grade I-II AVM and may be considered a front-line treatment, particularly for lesions in deep or eloquent locations. Preceding publications may be influenced by selection bias, with favorable AVMs undergoing resection, whereas those at increased risk of complications and nonobliteration are disproportionately referred for SRS.

Sections du résumé

BACKGROUND
No guidelines have been published regarding stereotactic radiosurgery (SRS) in the management of Spetzler-Martin grade I and II arteriovenous malformations (AVMs).
OBJECTIVE
To establish SRS practice guidelines for grade I-II AVMs on the basis of a systematic literature review.
METHODS
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant search of Medline, Embase, and Scopus, 1986-2018, for publications reporting post-SRS outcomes in ≥10 grade I-II AVMs with a follow-up of ≥24 mo. Primary endpoints were obliteration and hemorrhage; secondary outcomes included Spetzler-Martin parameters, dosimetric variables, and "excellent" outcomes (defined as total obliteration without new post-SRS deficit).
RESULTS
Of 447 abstracts screened, 8 were included (n = 1, level 2 evidence; n = 7, level 4 evidence), representing 1102 AVMs, of which 836 (76%) were grade II. Obliteration was achieved in 884 (80%) at a median of 37 mo; 66 hemorrhages (6%) occurred during a median follow-up of 68 mo. Total obliteration without hemorrhage was achieved in 78%. Of 836 grade II AVMs, Spetzler-Martin parameters were reported in 680: 377 were eloquent brain and 178 had deep venous drainage, totaling 555/680 (82%) high-risk SRS-treated grade II AVMs.
CONCLUSION
The literature regarding SRS for grade I-II AVM is low quality, limiting interpretation. Cautiously, we observed that SRS appears to be a safe, effective treatment for grade I-II AVM and may be considered a front-line treatment, particularly for lesions in deep or eloquent locations. Preceding publications may be influenced by selection bias, with favorable AVMs undergoing resection, whereas those at increased risk of complications and nonobliteration are disproportionately referred for SRS.

Identifiants

pubmed: 32065836
pii: 5739575
doi: 10.1093/neuros/nyaa004
pmc: PMC7426190
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

442-452

Informations de copyright

© Congress of Neurological Surgeons 2020.

Références

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):338-46
pubmed: 24726288
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
J Neurosurg. 1980 Oct;53(4):456-64
pubmed: 7420165
J Neurosurg. 2012 Jan;116(1):11-20
pubmed: 22077452
J Neurosurg. 1990 Sep;73(3):387-91
pubmed: 2384776
J Neurosurg. 2017 Mar;126(3):852-858
pubmed: 27058199
Acta Neurochir (Wien). 2017 Aug;159(8):1457-1478
pubmed: 28555270
J Neurosurg. 2014 Oct;121(4):878-90
pubmed: 25105704
Neurosurgery. 2000 Aug;47(2):389-96; discussion 397
pubmed: 10942012
Neurosurgery. 2002 Sep;51(3):614-23; discussion 623-7
pubmed: 12188939
J Neurosurg. 2002 Jan;96(1):79-85
pubmed: 11794608
J Neurosurg. 2015 Apr;122(4):912-20
pubmed: 25658789
Brain Res. 1989 Sep 4;496(1-2):241-50
pubmed: 2804633
Stroke. 2012 Sep;43(9):2497-9
pubmed: 22821608
J Neurosurg. 2013 Jan;118(1):74-83
pubmed: 23082882
Neurosurgery. 2007 Jul;61(1):39-49; discussion 49-50
pubmed: 17621017
Stroke. 2016 Feb;47(2):342-9
pubmed: 26658441
J Neurosurg. 2017 Apr;126(4):1056-1063
pubmed: 27285541
Neurosurgery. 2016 Apr;78(4):499-509
pubmed: 26990410
N Engl J Med. 2007 Jun 28;356(26):2704-12
pubmed: 17596605
J Neurosurg. 2017 Feb;126(2):486-494
pubmed: 27128584
Clin Neurosurg. 1979;26:307-13
pubmed: 544127
J Neurosurg. 2018 Jun;128(6):1850-1854
pubmed: 28665253
Oper Neurosurg (Hagerstown). 2020 Feb 1;18(2):136-144
pubmed: 31250901
Neurosurgery. 2012 Jun;70(6):1458-69; discussion 1469-71
pubmed: 22186841
J Neurosurg. 2019 Jan 11;132(1):122-131
pubmed: 30641831
J Neurosurg. 2011 Mar;114(3):842-9
pubmed: 20932095
Nat Rev Dis Primers. 2015 May 28;1:15008
pubmed: 27188382
J Neurosurg. 2013 Feb;118(2):437-43
pubmed: 23198804
Lancet. 2014 Feb 15;383(9917):614-21
pubmed: 24268105
Stroke. 2003 May;34(5):e29-33
pubmed: 12690217
World Neurosurg. 2017 Jun;102:507-517
pubmed: 28344176
J Neurol. 2013 Aug;260(8):2156-62
pubmed: 23712798
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):525-32
pubmed: 22027260
Neurosurgery. 2003 Apr;52(4):740-8; discussion 748-9
pubmed: 12657169
J Clin Neurosci. 2016 Jul;29:155-61
pubmed: 26947340
Neurosurgery. 2005;56(1):56-63; discussion 63-4
pubmed: 15617586
Acta Neurochir (Wien). 1992;117(3-4):129-34
pubmed: 1414513
Neurosurgery. 1997 Apr;40(4):664-72; discussion 672-4
pubmed: 9092839
N Engl J Med. 2017 May 11;376(19):1859-1866
pubmed: 28489992
J Neurosurg. 2017 Nov;127(5):1105-1116
pubmed: 28009228
Neurosurgery. 2007 Apr;60(4):638-46; discussion 646-8
pubmed: 17415200
Neurosurgery. 2017 Jun 1;80(6):991
pubmed: 28525927
Neurosurgery. 1996 May;38(5):906-14
pubmed: 8727815
J Neurosurg. 2012 Jan;116(1):44-53
pubmed: 22077450
Neurosurg Focus. 2001 Nov 15;11(5):e1
pubmed: 16466233
Neurosurgery. 2003 Feb;52(2):296-307; discussion 307-8
pubmed: 12535357
Neurosurgery. 2010 Apr;66(4):702-13; discussion 713
pubmed: 20190666
Stroke. 2003 May;34(5):1163-9
pubmed: 12702837
J Neurosurg. 2014 Aug;121(2):457-67
pubmed: 24605839
Neurol Res. 1998 Dec;20(8):673-83
pubmed: 9864730
J Neurosurg. 2013 Oct;119(4):981-7
pubmed: 23829820
J Neurosurg. 1986 Oct;65(4):476-83
pubmed: 3760956
Stroke. 2013 Feb;44(2):437-41
pubmed: 23287780
Neurosurgery. 2005 Oct;57(4):668-75; discussion 668-75
pubmed: 16239878
Neurosurgery. 2017 Dec 1;81(6):910-920
pubmed: 28645182
Neurosurgery. 2010 Mar;66(3):498-504; discussion 504-5
pubmed: 20173544
Clin Neurol Neurosurg. 2014 Sep;124:72-80
pubmed: 25019456
Neurosurgery. 2008 Aug;63(2):239-43; discussion 243
pubmed: 18797353
J Radiosurg SBRT. 2017;5(1):5-24
pubmed: 29296459
J Neurosurg. 2012 Jan;116(1):33-43
pubmed: 22077451

Auteurs

Christopher S Graffeo (CS)

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.

Arjun Sahgal (A)

Department of Radiation Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.

Antonio De Salles (A)

Department of Neurosurgery, University of California, Los Angeles, Los Angeles, California.

Laura Fariselli (L)

Fondazione IRCCS Istituto Neurologico Carlo Besta Milano, Unità di Radioterapia, Milan, Italy.

Marc Levivier (M)

Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Lijun Ma (L)

Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Ian Paddick (I)

National Hospital for Neurology and Neurosurgery, London, United Kingdom.

Jean Marie Regis (JM)

Department of Functional Neurosurgery, Timone University Hospital, Aix-Marseille University, Marseille, France.

Jason Sheehan (J)

Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.

John Suh (J)

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Shoji Yomo (S)

Division of Radiation Oncology, Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan.

Bruce E Pollock (BE)

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.
Department Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH